01 Stock Market
As of Feb 5, the U.S. major indexes closed as follows: Dow Jones up 0.53% at 49,501.30, S&P 500 down 0.51% at 6,882.72, and Nasdaq Composite down 1.51% at 22,904.58. A rotation into value helped the Dow finish higher, while tech dragged the Nasdaq as chip headlines ignited profit-taking in AI‑linked names.
Unusual-move stocks were active as chip and AI proxies swung sharply. In semis, AMD down 17.31% at $200.19, NVIDIA (NVDA) down 3.41% at $174.19, Micron (MU) down 9.55% at $379.40, and Broadcom (AVGO) down 3.83% at $308.05; leveraged chip funds followed, with SOXL down 13.09% at $53.19 and SOXS up 13.20% at $2.23. AI/data names saw pressure: Palantir (PLTR) down 11.62% at $139.54, Oracle (ORCL) down 5.17% at $146.67, Meta Platforms (META) down 3.28% at $668.99, while mega-cap Microsoft (MSFT) rose 0.72% to $414.19 and Apple (AAPL) rose 2.60% to $276.49. EV and space were mixed: Tesla (TSLA) down 3.78% at $406.01 and Rocket Lab (RKLB) down 10.04% at $73.11. Some commodity proxies firmed with AGQ up 5.56% at $175.49 and SLV up 2.88% at $79.18, while crypto‑exposed MSTR fell 3.13% to $129.09. Among single names, SNDK down 15.95% at $584.55, and SMCI up 13.78% at $33.76.
Performance among U.S.-listed Chinese ADRs skewed lower alongside mega-cap tech softness. Laggards included Bilibili (BILI) down 6.56% at $29.75, Baidu (BIDU) down 4.77% at $137.95, NetEase (NTES) down 5.41% at $121.41, Trip.com (TCOM) down 5.11% at $57.39, Kingsoft Cloud (KC) down 7.69% at $12.12, GDS down 6.97% at $41.25, and Tencent Music (TME) down 3.41% at $15.84. Bright spots included solar and travel: JinkoSolar (JKS) up 8.46% at $27.56, Silicon Motion (SIMO) up 6.60% at $128.37, and Yum China (YUMC) up 4.73% at $53.14. Foundry bellwether TSMC (TSM) finished down 2.98% at $325.74.
02 Other Markets
U.S. 10-year Treasury yield fell by 0.01%, latest at 4.28. USD/CNH was unchanged 0.00%, at 6.94; USD/HKD fell 0.01%, at 7.81. U.S. Dollar Index rose 0.04%, at 97.67. WTI crude futures fell 1.20%, at 64.36 USD/bbl; COMEX gold futures rose 1.73%, at 5,036.30 USD/oz.
03 Top News
Symbotic reported mixed results and guided higher revenue, lifting shares in extended trade.The company posted EPS slightly below consensus while revenue topped expectations, and management guided next‑quarter revenue to a range above the Street. Elevated short interest amplified the move, and leadership highlighted strong operational execution and product innovation benefits.
Tenable beat revenue and added a $150 million buyback while issuing cautious top‑line guidance. Management cited strong adoption of Tenable One and AI integration as growth drivers and expects unlevered free cash flow to improve. Guidance outlined modest sequential growth for the next quarter and set a full‑year revenue range as the company balances investment and profitability.
Arm’s licensing revenue missed estimates, and shares fell despite a stronger forward sales outlook. The company projected next‑quarter revenue above consensus on AI demand from data centers to smartphones but the licensing shortfall and handset headwinds weighed on sentiment. Royalty revenue grew briskly, underscoring broader adoption of Arm‑based designs.
Qualcomm issued a weaker outlook, citing a global memory shortage pressuring smartphone demand. Management said handset OEMs are reducing inventories due to tight memory supply, dragging near‑term revenue and EPS forecasts below consensus. The company noted its upcoming AI data center chips are not expected to be materially impacted by memory constraints.
Alphabet said capital expenditures could nearly double as it scales AI infrastructure, while revenue and profit beat. Management pointed to strong growth in Google Cloud and rising AI demand as justification for larger server and data center investments. Investors weighed the heavier capex profile against accelerating cloud momentum and broad‑based AI monetization.
Hims & Hers launched nationwide lab testing with Quest Diagnostics, expanding into preventive care. The program offers two annual tiers at $199 and $499, covering up to 120 biomarkers with virtual follow‑ups for personalized plans. Leadership expects the initiative to broaden the funnel beyond core categories and sees potential to scale to a multibillion‑dollar opportunity.
Enphase surged after beating earnings and guiding above expectations, sparking a solar rebound. The company reported better‑than‑expected EPS and revenue, and projected current‑quarter sales above the Street midpoint. Management cited improving U.S. sell‑through and product cycles, aiding peers such as JinkoSolar and SolarEdge in sympathy.
Boston Scientific posted higher earnings and sales, but shares dipped as guidance trailed bullish hopes. Cardiovascular and MedSurg units delivered double‑digit revenue growth, with adjusted EPS above consensus. The company projected continued top‑line expansion and margin progress, though investors had anticipated a more robust outlook.
Uber guided profit below estimates as affordability initiatives boosted trips but compressed margins, and announced a CFO transition. Management expects lower near‑term margin expansion due to cheaper ride options and tax effects, while forecasting gross bookings above consensus. The company named a new finance chief and reaffirmed its ambition to integrate autonomous ride services with partners.
Eli Lilly projected earnings above expectations on surging demand for obesity treatments and pipeline progress. The drugmaker delivered revenue and EPS beats and guided stronger profitability as Zepbound scales and an oral weight‑loss pill launch approaches. Management highlighted sustained momentum in metabolic health and capacity investments to meet demand.
Sources: Reuters, Dow Jones, Benzinga, Tiger Newspress, public market data
Disclaimer: This content is for reference only and does not constitute investment advice.
